Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome.
<h4>Purpose</h4>To report the significance of extraglandular ocular involvement and long-term systemic morbidity and mortality in primary Sjögren's Syndrome (SS).<h4>Methods</h4>This retrospective, longitudinal cohort study included consecutive patients with primary SS e...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0239769 |
| _version_ | 1819042456942936064 |
|---|---|
| author | Priya M Mathews Susan A Robinson Anisa Gire Alan N Baer Esen K Akpek |
| author_facet | Priya M Mathews Susan A Robinson Anisa Gire Alan N Baer Esen K Akpek |
| author_sort | Priya M Mathews |
| collection | DOAJ |
| description | <h4>Purpose</h4>To report the significance of extraglandular ocular involvement and long-term systemic morbidity and mortality in primary Sjögren's Syndrome (SS).<h4>Methods</h4>This retrospective, longitudinal cohort study included consecutive patients with primary SS evaluated at a tertiary referral center. An electronic chart review was performed and all available data were extracted from clinic visits between October 1999 and March 2019. The primary outcome measures included occurrence of extraglandular ocular manifestations of SS, serological markers, prevalence of malignancy, and incidence of death.<h4>Results</h4>One hundred and twenty-six SS patients with minimum 3 years of follow-up (median 9.6, range 3.0-15.9 years, total of 1,235 patient-years) were included. Of those, 10 patients with inflammatory keratolysis or scleritis had 2.3 times greater likelihood of death compared to the rest of the cohort (OR = 2.3, 95% confidence interval [CI] 0.5 to 4.0, p = 0.01) due to SS related complications. The lifetime prevalence of any malignancy in the entire cohort was 15.5%. The most common hematologic malignancy was non-Hodgkin's lymphoma (4.8%) and the most common solid malignancy was breast cancer (6.0%). Men SS patients were more likely to have a history of or concurrent malignancy compared to women (30.0% versus 13.7%, p = 0.16) and double the mortality (OR = 2.1, 95% CI 0.09 to 1.4, p = 0.04), independent of malignancy.<h4>Conclusions</h4>SS patients with serious ocular manifestations, particularly men, may be at greater risk for mortality due to SS complications. The eye seems to be the barometer of systemic disease activity. |
| first_indexed | 2024-12-21T09:41:11Z |
| format | Article |
| id | doaj.art-40a88fb224f147529754bed81d1b394e |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T09:41:11Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-40a88fb224f147529754bed81d1b394e2022-12-21T19:08:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01159e023976910.1371/journal.pone.0239769Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome.Priya M MathewsSusan A RobinsonAnisa GireAlan N BaerEsen K Akpek<h4>Purpose</h4>To report the significance of extraglandular ocular involvement and long-term systemic morbidity and mortality in primary Sjögren's Syndrome (SS).<h4>Methods</h4>This retrospective, longitudinal cohort study included consecutive patients with primary SS evaluated at a tertiary referral center. An electronic chart review was performed and all available data were extracted from clinic visits between October 1999 and March 2019. The primary outcome measures included occurrence of extraglandular ocular manifestations of SS, serological markers, prevalence of malignancy, and incidence of death.<h4>Results</h4>One hundred and twenty-six SS patients with minimum 3 years of follow-up (median 9.6, range 3.0-15.9 years, total of 1,235 patient-years) were included. Of those, 10 patients with inflammatory keratolysis or scleritis had 2.3 times greater likelihood of death compared to the rest of the cohort (OR = 2.3, 95% confidence interval [CI] 0.5 to 4.0, p = 0.01) due to SS related complications. The lifetime prevalence of any malignancy in the entire cohort was 15.5%. The most common hematologic malignancy was non-Hodgkin's lymphoma (4.8%) and the most common solid malignancy was breast cancer (6.0%). Men SS patients were more likely to have a history of or concurrent malignancy compared to women (30.0% versus 13.7%, p = 0.16) and double the mortality (OR = 2.1, 95% CI 0.09 to 1.4, p = 0.04), independent of malignancy.<h4>Conclusions</h4>SS patients with serious ocular manifestations, particularly men, may be at greater risk for mortality due to SS complications. The eye seems to be the barometer of systemic disease activity.https://doi.org/10.1371/journal.pone.0239769 |
| spellingShingle | Priya M Mathews Susan A Robinson Anisa Gire Alan N Baer Esen K Akpek Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. PLoS ONE |
| title | Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. |
| title_full | Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. |
| title_fullStr | Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. |
| title_full_unstemmed | Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. |
| title_short | Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. |
| title_sort | extraglandular ocular involvement and morbidity and mortality in primary sjogren s syndrome |
| url | https://doi.org/10.1371/journal.pone.0239769 |
| work_keys_str_mv | AT priyammathews extraglandularocularinvolvementandmorbidityandmortalityinprimarysjogrenssyndrome AT susanarobinson extraglandularocularinvolvementandmorbidityandmortalityinprimarysjogrenssyndrome AT anisagire extraglandularocularinvolvementandmorbidityandmortalityinprimarysjogrenssyndrome AT alannbaer extraglandularocularinvolvementandmorbidityandmortalityinprimarysjogrenssyndrome AT esenkakpek extraglandularocularinvolvementandmorbidityandmortalityinprimarysjogrenssyndrome |